Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Read MPK's full ASX announcement titled "Maiden MRE of 1.3 Moz at 1.54g/t Gold for Ferke" from 20 Apr 2026, on Market Index.